ORG
AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment
AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology
Senate Fails to Pass Bill Codifying Access to Contraception Amid Republican Opposition
Contraception, Senate Vote, Republican Opposition, Reproductive Rights, Birth Control
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Moon Surgical’s Maestro Robotic Laparoscopy Platform Receives FDA Clearance for Commercial Use
Moon Surgical, Maestro, Robotic Laparoscopy, FDA Clearance, Commercial Use, Surgical Innovation
GSK Acquires Oligonucleotide Partner Elsie for Up to $50 Million
GSK, Elsie Biotechnologies, oligonucleotide platform, acquisition, biotech, pharmaceuticals
Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook
Biopharma, Funding Levels, Federal Interest Rates, PitchBook, Venture Capital
Amgen’s Uplizna Achieves Phase 3 Success in Treating Immunoglobulin G4-Related Disease, Paving Way for Label Expansion
Amgen, Uplizna, Phase 3, Immunoglobulin G4-Related Disease, IgG4-RD, Rare Autoimmune Disease, Label Expansion
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings
ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing
ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet
Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry